Text Size: a  |   a 

FDA Approves First Auto-Injector for MS Treatment

September 30, 2015

The US FDA has now approved the first-ever electronic Auto-Injector for the treatment of Relapsing Remitting MS. Bayer’s BetaConnect system will be available early next year exclusively to patients taking Betaseron.

“Offering new options to individuals with MS to help manage their disease is important since ‘one size does not fit all' when considering MS treatment,” said Douglas Franklin, president and CEO of the Multiple Sclerosis Association of America in a statement. “Betaseron was the first disease-modifying therapy approved by the FDA to treat RRMS patients, and today we are pleased to offer the first and only electronic auto injector for those living with the disease,” added Klaus Marten, Bayer's VP and GM of neurology.

This system allows patients to customize their injection speed and depth settings to their liking. Also included is a back-up reminder that alerts the patient when it is time for the next injection. The system uses an audio/visual end-of-dose indicator, to alert the user that the injection is complete.